Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q4 2024 value amounting to $6.7 million.

  • Syndax Pharmaceuticals' Non-cash Items fell 8792.42% to $6.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year decrease of 8792.42%. This contributed to the annual value of $6.7 million for FY2024, which is 8792.42% down from last year.
  • As of Q4 2024, Syndax Pharmaceuticals' Non-cash Items stood at $6.7 million, which was down 8792.42% from $55.1 million recorded in Q4 2023.
  • Syndax Pharmaceuticals' Non-cash Items' 5-year high stood at $88.0 million during Q4 2022, with a 5-year trough of $83000.0 in Q1 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' median Non-cash Items value was $55.1 million (recorded in 2023), while the average stood at $45.8 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Non-cash Items crashed by 9973.82% in 2022, and later skyrocketed by 9363493.98% in 2023.
  • Syndax Pharmaceuticals' Non-cash Items (Quarter) stood at $81.9 million in 2020, then fell by 16.27% to $68.6 million in 2021, then rose by 28.29% to $88.0 million in 2022, then tumbled by 37.41% to $55.1 million in 2023, then plummeted by 87.92% to $6.7 million in 2024.
  • Its Non-cash Items stands at $6.7 million for Q4 2024, versus $55.1 million for Q4 2023 and $82.7 million for Q3 2023.